HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of zoledronate in the repair of chronically infarcted rat myocardium.

Abstract
Zoledronate (Zol), one of the class of bisphophonate drugs, is commonly used to treat postmenopausal osteoporosis. Treatment of liposomal bisphosphonates has been shown to worsen myocardial infarct repair in an experimental model. The purpose of this study was to investigate the effect of Zol in the repair of chronically infarcted myocardium without liposomal encapsulation to mimic the clinical setting. Zol (20 μg/kg, a dose known to treat experimental osteoporosis in rats, n = 15) was administered subcutaneously to female Sprague-Dawley rats 1 day before coronary artery ligation. Rats receiving phosphate-buffered saline (n = 12) were used as controls. Left ventricular function, infarct size, and remodeling were studied at 4 weeks postinfarction. Zol pretreatment did not affect left ventricular ejection fraction in hearts with myocardial infarction (49.5 ± 1.4% in Zol; 50.6 ± 2.1% in phosphate-buffered saline). Infarct size was similar in Zol versus untreated hearts (34.2% ± 2.9% in Zol; 33.4% ± 2.9% in phosphate-buffered saline). Left ventricular cavity volume and circumference, infarct thickness, and expansion index were comparable between the groups. To investigate a potential effect of Zol on tissue macrophage infiltration after myocardial infarction, heart specimens were harvested 48 hours postinfarction and sections were immunostained with CD68 antibody, a macrophage-specific marker. Results of macrophage immunostaining revealed that the level of tissue macrophage infiltration was similar between groups. In conclusion, administration of Zol before myocardial infarction had no adverse effects on cardiac contractile function, infarct size, or remodeling. These results suggest that treatment of Zol given before the onset of myocardial infarction does not cause worsening of infarct repair.
AuthorsHyosook Hwang, Sharon L Hale, Justin Leeka, Robert A Kloner
JournalJournal of cardiovascular pharmacology (J Cardiovasc Pharmacol) Vol. 56 Issue 6 Pg. 604-9 (Dec 2010) ISSN: 1533-4023 [Electronic] United States
PMID21052019 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Diphosphonates
  • Imidazoles
  • Zoledronic Acid
Topics
  • Animals
  • Chronic Disease
  • Diphosphonates (therapeutic use)
  • Female
  • Heart (drug effects)
  • Imidazoles (therapeutic use)
  • Myocardial Infarction (drug therapy, metabolism, pathology)
  • Myocardium (pathology)
  • Random Allocation
  • Rats
  • Rats, Sprague-Dawley
  • Zoledronic Acid

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: